![]() The Interactive Multi-Criteria Decision Making method (TODIM, in Portuguese) was applied to reveal the individual preferences and the fuzzy aggregation functions to obtain the group preferences. METHODS: The priority setting consisted in obtaining the preferences of eight stakeholders (physicians and pharmacists) members of a National Committee, related to three medicines: carfilzomib for relapsed multiple myeloma nivolumab for unresectable or metastatic melanoma and palbociclib for advanced breast cancer with estrogen receptor positive and human epidermal growth factor receptor 2 negative (HER2). CA2: THE MULTI-CRITERIA DECISION ANALYSIS IN THE PRIORITY SETTING OF EMERGING MEDICINES Nascimento A, Almeida RT,Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil OBJECTIVES: To describe an approach to set priority of emerging medicines for Horizon Scanning in the Brazilian National Health System (SUS, in Portuguese). CONCLUSIONS: Significant differences in the timing of HTA decisions, nuances in the indications chosen for submission, along with challenging success rates and reimbursement criteria, highlight the growing importance of the HTA hurdle for oncology medications in Latin America. While manufacturers may also submit sequentially to different countries, the availability of decisions varied significantly between continents, with Latin American HTA decisions rendered on average 25 and 50 months after pCODR and NICE, respectively. Overall timelines for HTA processes were variable and often unclear. Nearly half (45%) of the HTA decisions were negative due to limited clinical evidence or uncertainty around cost-effectiveness. Limited parallel assessments (similar medications and indications reviewed concurrently by different HTAs) were found. RESULTS: Within the 5-year timeframe observed, 22 HTA assessments were identified for 10 oncology treatments (1-4 indications/medication). Matching HTA appraisals from Canada (pCODR) and UK (NICE) for these same medications were reviewed for extraction and analysis. HTA reports and most comprehensive information were available in Brazil, Columbia and Uruguay so these were retained for this assessment. METHODS: Publicly available HTA appraisals from Latin America for oncology medications published since January 2012 were reviewed (original language) and summarized by decision, date, reimbursement criteria/covered patient population, supporting data and rationale. This study aimed to understand recent decisions and recommendations for novel oncology medications by HTA agencies in Latin America and compare important characteristics with corresponding appraisals issued in Canada and the UK. ![]() While healthcare systems, health policy priorities, and implementation of HTA processes vary between countries, HTA appraisals from various agencies for a product in a specific indication are often centered on similar clinical trial evidence and country-specific economic data submitted by manufacturers. RESEARCH PODIUM PRESENTATIONS CANCER STUDIES CA1: COMPARATIVE ASSESSMENT OF LATIN AMERICAN HTA APPRAISALS FOR ONCOLOGY Arvin-Berod C1, Benjamin N2, Martel M3,1Xcenda Switzerland GmbH, Bern, Switzerland, 2Xcenda, LLC, Palm Harbor, FL, USA, 3Xcenda (UK) Ltd, London, UK OBJECTIVES: In the last decade, Health Technology Assessment (HTA) organisations in Latin America have continued to evolve as key stakeholders in the healthcare decision-making continuum.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |